CymaBay Therapeutics, Inc. is a Hayward-based biopharmaceutical company dedicated to transforming the lives of individuals suffering from chronic liver, digestive tract, or inflammatory diseases. Through innovative medicines that target the underlying causes of these conditions, CymaBay aims to restore health and improve the quality of life for patients.
Driven by a patient-inspired approach and a commitment to scientific advancement, CymaBay pioneers research in liver, metabolic, and inflammatory diseases, offering promising treatments that alleviate symptoms and slow disease progression. Their lead compound, seladelpar, is the first of its kind developed for the treatment of Primary Biliary Cholangitis (PBC), supported by an extensive development program.
Generated from the website